| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_783eead46dcb28054952c78a85f52f4e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-515 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2019-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc0d307f981f3d710ff8de0fbfc49212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e2d28ed90129b4f58c395a60bc5e7e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b887e6d56f870bb188989dcadf8874b6 |
| publicationDate |
2020-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111818941-A |
| titleOfInvention |
Natural killer cells against transforming growth factor beta |
| abstract |
Described is a NK cell with low SMAD3 expression and altered gene expression profile to generate high cytokine expression and TGF-beta superfamily resistance, which is referred to herein as a natural TGF-beta superfamily imprinted NK cell Killer cells (TGFβi NK cells). A method of treating cancer or infection in a subject in need thereof is described. The method includes administering to the subject a therapeutically effective amount of TGFβi NK cells. A method of producing TGFβi NK cells is described by in vitro activation of natural killer cells in the presence of TGF-β superfamily cytokines. |
| priorityDate |
2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |